The Valley Fever Center for Excellence (VFCE) at the University of Arizona College of Medicine – Tucson has been awarded a four-year, $4.8 million grant for research to speed development of a vaccine to combat Valley fever, the sometimes deadly respiratory illness caused by Coccidioides spores found in soils of the U.S. Southwest.
The funding comes from the National Institute of Allergy and Infectious Diseases (NIAID), a unit of the National Institutes of Health (NIH), and aims to enable development of a live, yet safe, vaccine to prevent this fungal disease (also known as coccidioidomycosis, or cocci).
“We are very excited to receive this award,” said John N. Galgiani, MD, principal investigator on the project, a UA professor of medicine and the center’s founding and current director. “This reflects the scientific validity of our plans and the funds will greatly accelerate the vaccine’s development.”
The live vaccine candidate is known as delta-CPS1 and was invented at the UA. It was developed by a multi-disciplinary team of co-investigators on this and prior grants led by Marc J. Orbach, PhD, a fungal geneticist and UA professor of plant sciences in the College of Agriculture and Life Sciences (CALS), that includes Dr. Galgiani, Jeffrey Frelinger, PhD, UA professor of immunobiology; and Lisa Shubitz, DVM, a VFCE associate research professor with a dual appointment in the College of Medicine – Tucson and the CALS School of Animal and Comparative Biomedical Sciences. The vaccine has already protected mice from Valley fever, but has never been tested on dogs.
The research goal is to test and develop this vaccine to protect dogs from contracting Valley fever. Anivive Lifesciences Inc., a California-based biotechnology company, has licensed the vaccine from the UA through Tech Launch Arizona and will provide additional investment and expertise to fully develop this dog vaccine. Tech Launch is the UA’s commercialization arm, helping transform UA innovations and discoveries into intellectual property, inventions and technology through licensing agreements with private industry. The UA BIO5 Institute also has assisted in this translational project.
Scientists at Colorado State University also are collaborating on this project through CSU’s College of Veterinary Medicine and Biomedical Sciences and the lab of Richard A. Bowen, DVM, PhD. If proven safe and effective in dogs, the next step likely would be evaluation and possible approval of a vaccine to prevent Valley fever in humans.
“The awarding of this grant to Dr. Galgiani’s group will serve to help us advance the introduction of a vaccine for both man and animals to prevent this truly devastating disease,” said David Bruyette, DVM, DACVIM, chief medical officer at Anivive Lifesciences.
This recent award comes on the heels of a $2.7 million NIH/NIAID grant the VFCE also received for collaborative work to understand the human genetics behind susceptibility to the worst forms of Valley fever (supported by NIAID under Award No. U01AI122275). That research addresses the question of why some people get so sick from this fungus while other’s immune systems are able to control it, resulting in only a mild illness, if any at all. These efforts could lead to precision medicine solutions specific to an individual at risk and possible new approaches to treatment by immunologic response modifiers.
With more than 90 percent of U.S. human infection cases occurring in Arizona and California, Valley fever is the most significant fungal public health problem in the Southwest. Each year, Valley fever is responsible for 50,000 illnesses and more than 150 deaths, with a cost of half a billion dollars in health care and lost productivity, according to the U.S. Centers for Disease Control and Prevention. Current therapies for more severe instances of this disease are not curative and may need to be continued for life.
This research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under Award No. R01AI132140. The content solely is the responsibility of the authors and does not necessarily represent the official views of the NIH.
EDITORS/REPORTERS, PLEASE NOTE: The UA Office of Communications hosts a website — “UA Expertise on Valley Fever (Coccidioidomycosis)”— available with additional information, photo and video resources.
About the Valley Fever Center for Excellence
In 1996, the Arizona Board of Regents established the Valley Fever Center for Excellence at the University of Arizona to address problems created by the fungus, Coccidioides, the cause of Valley fever. Some cases are mild; some so severe that it spreads past the lungs. It also affects animals, including pets and livestock. The center works to spread public awareness and education about Valley fever, promote high-quality care for the disease and pursue research to improve treatment therapies and develop a vaccine. To learn more, please visit vfce.arizona.edu
About the University of Arizona College of Medicine – Tucson
The University of Arizona College of Medicine – Tucson is advancing health and wellness through state-of-the-art medical education programs, groundbreaking research and advancements in patient care in Arizona and across the United States. Founded in 1967, the College ranks among the top medical schools in the nation for research and primary care and is leading the way in academic medicine through a partnership with Banner – University Medicine, a new division of one of the largest nonprofit health care systems in the nation. For more information: www.medicine.arizona.edu
About the University of Arizona Health Sciences
The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. The UA Health Sciences includes the UA Colleges of Medicine (Phoenix and Tucson), Nursing, Pharmacy and Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the growing Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, the UA Health Sciences reaches across the state of Arizona and the greater Southwest to provide cutting-edge health education, research, patient care and community outreach services. A major economic engine, the UA Health Sciences employs almost 5,000 people, has nearly 1,000 faculty members and garners more than $126 million in research grants and contracts annually. For more information: http://uahs.arizona.edu. Follow us: Facebook | Twitter | YouTube | LinkedIn
ALSO SEE:
"University of Arizona gets $4.8 million federal grant to develop valley fever vaccine for dogs" | Arizona Daily Star, Posted Aug. 24, 2017
"NIH Awards $4.8M Grant to UA Valley Fever Center for Excellence to Accelerate Vaccine Development" | Original DOM News webposting, Posted Aug. 22, 2017
NOTE: This release has been edited to add co-investigators on the grant who made up team leads in development of the delta-CPS1 live vaccine candidate invented at the University of Arizona.